News Bayer CEO warns of tough 2025 as turnaround plan beds in Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.
News BMS extends its cost-cutting drive by another $2bn BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.
News Pressure relieved on AZ as details of Chinese probe emerge AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.
News GSK rides out vaccine sales weakness with cancer, HIV gains Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.
News Novo rises on Wegovy sales leap, but warns of a slowdown Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News GSK ends decades-long hiatus in oral antibiotics for UTIs The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl